Previous studies have shown that increased hepatic CCL2 recruits CCR2-positive monocytes, exacerbating inflammation, fibrosis, and steatosis in MASLD patients [30,31,32]. Here, CCL2 is linked to metabolic dysfunction-associated steatotic liver disease.